GE Healthcare Expands Single-Use Manufacturing Capabilities
News Nov 11, 2016
GE Healthcare’s Life Sciences business has announced a USD 7 million expansion project at its single-use technology manufacturing facility in Westborough, MA, US. The expanded site will manufacture a range of single-use products, including cell growth bags, based on a newly developed film platform resulting from GE’s strategic alliance with Sealed Air.
With global demand predicted to exceed USD 3 billion by 2020(1), single-use bioprocessing technologies are playing an increasingly vital role to biologic producers, helping them accelerate capacity expansion and improve productivity to support faster delivery of targeted therapies to patient populations. GE’s tripling of production-dedicated clean room capacity at Westborough and upskilling of over 300 personnel will enable the business to confidently meet increasing market demand well into the future.
In addition, the installation of automated production lines will drive manufacturing efficiency and improved process controls to ensure product quality and consistency. The new film platform, developed in collaboration with Sealed Air expressly for biomanufacturing, supports exceptional cell growth and application robustness.
It will be used in the manufacture of all single-use products at the Westborough site. In parallel, GE Healthcare Life Sciences has established an enlarged extractables and leachables (E&L) analytical laboratory in Uppsala, Sweden. This laboratory will support in-depth characterization of the potential impact of E&L compounds across all production processes and future novel single-use technology materials.
Jan Makela, General Manager, BioProcess at GE Healthcare’s Life Sciences business said: “Biopharmaceuticals are complex to make, requiring a dependable, consistent supply of high quality manufacturing technologies. Single-use is top of mind for our customers, for its ability to flex production to meet market needs. The launch of our new film with Sealed Air, the investment in single-use manufacturing in Westborough, MA and the enlarged E&L capabilities in Sweden confirm our on-going commitment to minimizing risk and assuring security of supply for our customers around the globe. Our enhanced position in single-use bioprocessing ensures we are fully prepared to support the industry’s rapid growth.”
Source: Story from GE Healthcare Life Sciences. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu VaccineNews
Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.READ MORE
Key to Creating Better Medicines with Less Side EffectsNews
A new study published in Science by Professors Yossi Paltiel of the Hebrew University of Jerusalem and Ron Naaman from the Weizmann Institute of Science describes a breakthrough technology with the power to create drugs with fewer unwanted side effects.
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018